Screener / SEC EDGAR /CIK 0000790526 /10-K filed Mar 2, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

RadNet, Inc. RDNT

Compare with peers Embed
The 10-K against last year's

105 changes: 32 added, 25 removed, 43 reworded, 5 quiet changes

10-K Mar 2, 2026 vs Mar 3, 2025

10-K 0001628280-26-013337 (Mar 2, 2026) vs 10-K 0001628280-25-009481 (Mar 3, 2025) Not compared: Legal Proceedings.

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

184 paragraphs · 2 new · 35 reworded · 1 gone · 10-K Mar 2, 2026 against Mar 3, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 162 · 46% changed Every version of it
In some states, the law prohibits or limits insurance coverage for the risk of punitive damages arising from professional liability and general liability claims or litigation. Coverage for punitive damages is also excluded under some insurance policies. As a result, we may be liable for punitive damage awards in these states that either are not covered or are in excess of our insurance policy limits. Claims against us, regardless of their merit or eventual outcome, could also inhibit our ability to attract patients or expand our business and could require our management to devote time to matters unrelated to the day-to-day operation of our business.
Paragraph 89 · 41% changed Every version of it
Additionally, we and our third parties leverage AI and machine learning tools to increase productivity and innovation. We also face potential risks from the use of AI and machine learning tools. Our, or our customers’ sensitive, proprietary, or confidential information could be leaked, disclosed, or revealed as a result of or in connection with employees’ or vendors’ use of generative AI technologies. In addition, we may use AI outputs to inform certain decisions, and AI models may create incomplete, inaccurate, or otherwise flawed outputs, some of which may appear correct. Due to the potential flaws in the use of AI, we could make incorrect decisions, including decisions that could bias certain individuals or classes of individuals and adversely impact their rights. The rapid development of AI tools could render obsolete certain technologies or tools we currently use, or otherwise provide competitors with a technological edge. New or evolving legislation or regulations might impose restrictions on how AI and machine learning tools can be used, requiring us to adapt our tools or face various penalties for non-compliance, including potential disgorgement of data and associated capabilities. As a result, we could face adverse consequences, including exposure to reputational and competitive harm, customer loss, and legal liabilities. The AI tools may also be subject to additional, and as yet unidentified, security threats.
Paragraph 135 · 35% changed Every version of it
Our current substantial indebtedness and any future indebtedness we incur could adversely affect our financial condition. We are highly leveraged. As of December 31, 2024 2025 term loan indebtedness, excluding related discount, was $1,005.6 $1,084.9 million, of which $961.1 million was borrowed pursuant to the Barclays credit facility term loans were $870.6 Revolving Credit Facility and the Barclays Term Loan and which includes $123.7 million borrowed pursuant to the Truist Revolving Credit Facility and the Truist credit facility term loan was $135.0 million. Term Loan (as such capitalized terms are defined in the notes to our consolidated financial statements, and collectively, the "Barclays and Truist Credit Facilities") at our New Jersey Imaging joint venture. The Company is neither a borrower or guarantor under the Truist Credit Facilities. Our substantial indebtedness could also:
Paragraph 120 · 34% changed Every version of it
The laws of certain states prohibit us from exercising control over the medical judgments or decisions of physicians and from engaging in certain financial arrangements, such as splitting professional fees with physicians. These laws are enforced by state courts and regulatory authorities, each with broad discretion. A component of our business has been to enter into management agreements with radiology practices. We provide management, administrative, technical and other non-medical services to the radiology practices in exchange for a service fee typically based on a percentage of the practice’s revenue. We structure our relationships with the radiology practices, including the purchase of diagnostic imaging centers, in a manner that we believe keeps us from engaging in the practice of medicine or exercising control over the medical judgments or decisions of the radiology practices or their physicians, or violating the prohibitions against fee-splitting. State laws and enforcement efforts regarding corporate practice of medicine and fee-splitting are often subject to change. As a consequence, there can be no assurance that our present arrangements with the Group or the physicians providing medical services and medical supervision at our imaging centers will not be challenged, and, if challenged, that they will not be found to violate the corporate practice of medicine or fee splitting prohibitions. Any violation would subject us to potential damages, injunction and/or civil and criminal penalties or require us to restructure our arrangements in a way that would affect the control or quality of our services and/or change the amounts we receive under our management agreements.
Paragraph 177 · 33% changed Every version of it
We currently anticipate that we will retain any future earnings to finance the continued development, operation and expansion of our business. As a result, we do not anticipate declaring or paying any cash dividends or other distributions in the foreseeable future. Further, if we were to enter into a credit facility or issue debt securities or preferred stock in the future, we may become contractually restricted from paying dividends. If we do not pay dividends, our common stock may be less valuable because stockholders must rely on sales of their common stock after price appreciation, which may never occur, to realize any gains on their investment.
Paragraph 31 · 25% changed Every version of it
Any reduction in the rate that we can charge for our imaging services under these programs will reduce our net revenues and our operating margins per procedure under those reimbursement programs. Unless we can secure additional procedure volumes, increase utilization of our equipment, or change the overall mix of service procedures that we provide, a decline in reimbursement rates will reduce our net revenues and results of operations.
Paragraph 176 · 23% changed Every version of it
We currently anticipate that we will retain any future earnings to finance the continued development, operation and expansion of our business. As a result, we do not anticipate declaring or paying any cash dividends or other distributions in the foreseeable future. Further, if we were to enter into a credit facility or issue debt securities or preferred stock in the future, we may become contractually restricted from paying dividends. If we do not pay dividends, our common stock may be less valuable because stockholders must rely on sales of their common stock after price appreciation, which may never occur, to realize any gains on their investment.
Paragraph 30 · 22% changed Every version of it
Any reduction in the rate that we can charge for our imaging services under these programs will reduce our net revenues and our operating margins per procedure under those reimbursement programs. Unless we can secure additional procedure volumes, increase utilization of our equipment, or change the overall mix of service procedures that we provide, a decline in reimbursement rates will reduce our net revenues and results of operations.

MD&A

112 paragraphs · 30 new · 43 reworded · 24 gone · 10-K Mar 2, 2026 against Mar 3, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 94 · 49% changed
Cash provided by operating financing activities for the year ended December 31, 2024 included $289.5 2025 decreased by $325.7 million in net income reconciling adjustments offset by a $56.5 million change in assets and liabilities. The $12.2 million increase in cash provided by operating activities for compared to the year ended December 31, 2024. Financing activity in 2024 compared to December 31, 2023 was included a public equity offering that generated $218.4 million in net proceeds and a refinancing of the Barclays Revolving Credit Facility that resulted in an additional $167.9 million of cash. In 2025, financing activity primarily driven consisted of a $100.0 million incremental term loan under the Barclays Credit Agreement, partially offset by an increase in income from operations. repayment of term loans, notes, and lease payables of $27.8 million.
Paragraph 76 · 45% changed
For the year ended December 31, 2023 2025, we recognized equity in earnings from unconsolidated joint ventures net income attributable to noncontrolling interests of $6.4 $35.7 million versus $10.4 $36.0 million for the year ended December 31, 2022, 2024, a decrease of $4.0 million or 38.1%. The decrease in equity in earnings from unconsolidated joint ventures was due to the formation of Arizona Diagnostic Radiology Group in November 2022, which operated at a net loss in 2023. $0.3 million.
Paragraph 60 · 44% changed
Stock-based compensation For the year ended December 31, 2025, Digital Health segment revenues increased $3.6 $27.0 million or 41.1%, to $92.7 million, or 17.1%, compared to approximately $24.6 $65.7 million for the year ended December 31, 2023 compared to $21.0 million for the year ended December 31, 2022. 2024. The growth was primarily driven by a 64.9% increase in AI-related revenue and a 29.0% increase in Enterprise Imaging revenue.
Paragraph 41 · 43% changed
Our 9.8% increase in same center revenue over the same period last year was driven by increases in fees charged per imaging procedure and an increase in procedures volumes. Same center total procedure volume grew at an overall rate of 3.2% which was comprised of a 1.7% increase in routine imaging and an 8.1% increase in advanced modality imaging procedures. The increase in revenue was largely attributable to the procedural volume growth, increased reimbursement from commercial and capitated payors and favorable changes in product mix, as advanced imaging was represented a greater portion proportion of overall total procedures. A significant contributor to the change in product mix this shift was the increase in PETHC PET CT procedures related to prostate cancer and suspect Alzheimer’s Alzheimer’s-related studies, which are included in within advanced modality imaging procedures.
Paragraph 70 · 42% changed
The increase decrease in interest expense was the result in the general increase in term loan debt primarily due to the refinancing repricing transaction of our Barclays credit facility Revolving Credit Facility (as defined in April the notes to our consolidated financial statements) in the fourth quarter of 2024, partially offset by which resulted in lower interest rates compared to the same period in the prior year. This benefit was partially offset by the $100.0 million of incremental term loan borrowings under our existing Barclays Revolving Credit Facility in the second quarter of 2025. See Note 8, Credit Facilities and Notes Payable, included in the notes to our consolidated financial statements.
Paragraph 109 · 42% changed
ACCOUNTS RECEIVABLE – Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. We continuously monitor collections from our payors and maintain an allowance for credit losses based upon specific payor collection issues that we have identified and our historical experience.
Paragraph 51 · 40% changed
In Thousands Year Years Ended December 31, Interest Expense 2025 2024 2023 $ Increase/(Decrease) % Change Total Interest Expense $79,849 $64,483 $15,366 23.8% Interest related to derivatives* $(762) $(9,752) Interest related to amortization** $2,276 $2,987 Adjusted Interest Expense*** $78,335 $71,248 $7,087 9.9% Other Operating Expenses $355,225 $303,952 $51,273 16.9%
Paragraph 88 · 40% changed
Balance Sheet Data as of December 31, 2024 2023 2022 Cash and cash equivalents $ 740,020 $ 342,570 Accounts receivable 185,821 163,707 Working capital (exclusive of current operating lease liability) 596,158 197,805 Stockholders' equity 1,133,410 813,359 Income Statement data for the years ended December 31, 2025 2024 2023 Total revenue $ 2,040,210 $ 1,829,664 $ 1,616,630 $ 1,430,061 Net (loss) income attributable to RadNet RadNet, Inc. common stockholders (18,652) 2,793 3,044 10,650

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors166 words changed in this paragraph; it is 52% similar to last year's version.
The laws of certain states prohibit us from exercising control over the medical judgments or decisions of physicians and from engaging in certain financial arrangements, such as splitting professional fees with physicians. These laws are enforced by state courts and regulatory authorities, each with broad discretion. A component of our business has been to enter into management agreements with radiology practices. We provide management, administrative, technical and other non-medical services to the radiology practices in exchange for a service fee typically based on a percentage of the practice’s revenue. We structure our relationships with the radiology practices, including the purchase of diagnostic imaging centers, in a manner that we believe keeps us from engaging in the practice of medicine or exercising control over the medical judgments or decisions of the radiology practices or their physicians, or violating the prohibitions against fee-splitting. State laws and enforcement efforts regarding corporate practice of medicine and fee-splitting are often subject to change. As a consequence, there can be no assurance that our present arrangements with the Group or the physicians providing medical services and medical supervision at our imaging centers will not be challenged, and, if challenged, that they will not be found to violate the corporate practice of medicine or fee splitting prohibitions. Any violation would subject us to potential damages, injunction and/or civil and criminal penalties or require us to restructure our arrangements in a way that would affect the control or quality of our services and/or change the amounts we receive under our management agreements.

Source: Item 1A, 10-K 0001628280-26-013337 vs Item 1A, 10-K 0001628280-25-009481

Accounting Policies146 words changed in this paragraph; it is 56% similar to last year's version.
At inception, we designated our 2019 Swaps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e. change in fair value) is reported as a component of other accumulated comprehensive loss in the consolidated statement of equity. The remaining gain or loss, if any, is recognized currently in earnings. The cash flows for both our $400,000,000 notional interest rate swap contract locked in at 1.98% due October 2025 and our $100,000,000 notional interest rate swap contract locked in at 1.89% did not match the cash flows for our Barclays term loans and so we Effective July 1, 2020, it was determined that they were not currently effective as cash flow hedges. Accordingly, hedge accounting no longer applied and accordingly after that date all changes in their the fair value after April 1, 2020 for of the $400,000,000 notional and after July 1, 2020 for the $100,000,000 notional was swaps is recognized in earnings. As of July 1, 2020, the total change in fair value relating to swaps included in other comprehensive income was approximately $24.4 million, net of taxes. This amount will be amortized to interest expense through October 2023 at approximately $0.4 million per month and continuing at approximately $0.3 million per month through October 2025.

Source: Item 8, Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, 10-K 0001628280-26-013337 vs Item 8, Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, 10-K 0001628280-25-009481

MD&A131 words changed in this paragraph; it is 55% similar to last year's version.
In addition to our imaging business, we established a Digital Health business segment in during our 2024 fiscal year, which combines our former Artificial Intelligence (“AI”) business segment AI businesses with our eRad, Inc. business. Our digital health Digital Health segment develops and delivers AI-powered health informatics solutions to drive improve quality, efficiency, and diagnostic outcomes in diagnostic imaging and radiology. We are using AI to develop solutions to assist radiologists and other clinicians in interpreting images and improving radiologist efficiency and patient care. The portfolio of AI and software solutions is anchored by eRad, Inc.'s RIS/PACS, informatics designed specifically for outpatient radiology Enterprise Operations solutions (traditionally knowns as RIS), Enterprise Imaging solutions (traditionally known as PACS), and Clinical AI solutions, enabled by the DeepHealth OS, a cloud-native operating system that helps operate all connects critical aspects of the radiology service line from scheduling and patient preparation to technologist workflow to interpretation and referral management. Our Clinical AI solutions currently cover the fields of diagnosis and screening in the domain of breast, prostate, lung, thyroid, and brain. Across our portfolio of AI solutions, we have 22 FDA clearances and 15 CE marks. Our Digital Health segment provides these solutions to RadNet and to over 2000 customers in the U.S. and outside of the U.S.

Source: Item 7, 10-K 0001628280-26-013337 vs Item 7, 10-K 0001628280-25-009481

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of RDNT's Risk Factors and MD&A, 10-K Mar 2, 2026 against 10-K Mar 3, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
contamination or injury from these hazardous materials. Although we maintain professional liability insurance coverage in amounts we believe is consistent with industry practice in the event of an accident, we could be held liable for any resulting damages, and any liability could exceed the limits of or fall outside the coverage of our professional liability insurance.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
Relatedly, reimbursement rate cuts may be pursued as a cost-saving measure by third party third-party payors resulting from the implementation of the federal No Surprises Act (H.R. 133) and similar insurer-provider payment dispute laws, which also may negatively impact our revenue.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
Also, the various radiology groups’ ability to continue performing under the management agreements may be curtailed or eliminated due to the radiology groups’ own financial difficulties, loss of physicians or other circumstances.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
In addition, we may use AI outputs to inform certain decisions, and AI models may create incomplete, inaccurate, or otherwise flawed outputs, some of which may appear correct.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
Our competitors include independent imaging operators, such as Akumin, Inc., private equity-backed chains, and smaller regional operators, as well as hospitals, clinics and radiology groups that operate their own imaging equipment.
Read it in 10-K Mar 2, 2026 at sec.gov
Show the other 42
RewordedRisk Factors
Further, if we were to enter into a credit facility or issue debt securities or preferred stock in the future, we may become contractually restricted from paying dividends.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
As part of our continued strategic expansion in Digital Health, we recently completed three acquisitions: iCAD, Inc., an AI-powered breast health solutions company; See-Mode Technologies, which enhances ultrasound-based diagnostics through artificial intelligence; and CIMAR (UK) Limited, which provides cloud-based medical image storage, PACS, and AI-enabled imaging workflow solutions. We are currently integrating these businesses into our Digital Health segment
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
On June 2, 2025, through our wholly owned subsidiary DH AI International Holdings, B.V, we acquired all of the equity interest in See-Mode Technologies (“See-Mode”), a medical technology company focused on using artificial intelligence to enhance ultrasound-based diagnostics.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
On July 17, 2025, we completed the acquisition of all of the outstanding equity interests of iCAD, Inc. (“iCAD”), a global leader in AI-powered breast health solutions. The acquisition integrates iCAD’s commercial, technology, and regulatory capabilities with those of DeepHealth, our wholly owned subsidiary within the Digital Health segment. The transaction strengthens DeepHealth’s position as an industry leader in AI-enabled breast cancer image interpretation and workflow optimization and expands its global market reach.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
The transaction was accounted for as the acquisition of a business and was completed through an all-stock exchange, with total purchase consideration of approximately $110.7 million based on the fair value of our common stock issued to iCAD shareholders and the fair value of our options issued in exchange for outstanding iCAD options.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
We allocated the purchase price to the assets acquired and liabilities assumed based on their estimated fair values, which resulted in the recognition of goodwill of approximately $36.6 million, primarily reflecting expected synergies from integrating iCAD’s technology portfolio, established customer relationships, and assembled workforce. In addition, we recorded identifiable intangible assets related to backlog, developed technology, customer relationships, and trade name totaling
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
approximately $38.3 million, consisting of $1.8 million, $0.7 million, $6.8 million, and $29.0 million, respectively, deferred tax asset, net of $20.6 million, Cash, deposits and others of $14.2 million, and property and equipment of $1.1 million.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
In connection with the iCAD acquisition, the Company identified and measured the fair values of acquired intangible assets, including backlog, trade names, developed technology, in-process research and development (“IPR&D”), and customer relationships. The valuations were performed using the income approach, consistent with market participant assumptions. The income approach incorporated assumptions such as projected revenues, estimated customer attrition, royalty rates, and discount rates reflecting market participant expectations. IPR&D projects were determined to have no material fair value as of the acquisition date. The identified intangible assets were assigned estimated useful lives as follows: backlog — approximately 4 years; trade names — approximately 1 year; developed technology — approximately 7 years; and customer relationships — approximately 15 years.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
On November 10, 2025, the Company completed the acquisition of all outstanding shares of CIMAR (UK) Limited (“CIMAR”), a United Kingdom–based provider of medical image storage and cloud-based PACS solutions. The acquisition was accounted for as a business combination.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
The total purchase consideration was approximately $37.0 million, consisting of $13.2 million in cash, $14.8 million in RadNet common stock issued after year end, a holdback of $3.2 million, and contingent consideration with a fair value of approximately $5.8 million as of the acquisition date, payable upon the achievement of specified recurring revenue targets.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
The purchase consideration was preliminarily allocated to the assets acquired and liabilities assumed based on their estimated fair values, resulting in the recognition of goodwill of approximately $20.1 million, which is primarily attributable to expected synergies from integrating CIMAR’s technology and operations with the Company’s Digital Health platform.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
Identifiable intangible assets recognized totaled approximately $22.3 million, consisting primarily of customer relationships of approximately $19.7 million, National Health Service ("NHS") and International Organization for Standardization ("ISO") certifications of approximately $2.2 million, and trade names of approximately $0.5 million. In addition, the Company recorded current net liabilities of approximately $0.3 million. The Company also recognized deferred tax liabilities of approximately $5.7 million in connection with the acquisition..
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
The identifiable intangible assets were valued using income- and cost-based valuation methodologies in accordance with ASC 805. Customer relationships were valued using the multi-period excess earnings method, which considers projected revenues, customer attrition, contributory asset charges, and a market-based discount rate. Trade names were valued using the relief-from-royalty method, based on projected revenues, an estimated royalty rate, and a market-based discount rate. NHS and ISO certifications were valued using a cost approach based on estimated replacement cost. The estimated useful lives are approximately 21 years for customer relationships, 4 years for trade names, and 1 years for certifications.
Read it in 10-K Mar 2, 2026 at sec.gov
RemovedMD&A
Further, we are using AI to develop solutions that employ machine learning to assist radiologists and other clinicians in interpreting images and improving radiologist efficiency and patient care. These AI solutions will initially be focused in the fields of screening for breast, prostate, lung and colon cancers. Our DeepHealth, Inc. subsidiary received FDA clearance for use of its SaigeQ "triage"/workflow product, SaigeDX advanced diagnostic product and Saige-Density breast density assessment software for screening breast mammography, which we have begun to roll out in certain markets as an Enhanced Breast Cancer Detection solution. Our Aidence Holding B.V. subsidiary is developing solutions for interpretation of chest and lung CT scans for lung cancer screening. The Aidence Holding B.V. subsidiary has received the CE marking for these solutions and has existing customers in seven European countries, with its largest concentration in the United Kingdom, and plans to submit an application for FDA clearance to sell in the United States. Our Quantib B.V. subsidiary is primarily focused on interpretation of prostate MRI for widespread prostate cancer screening. Quantib’s prostate MRI post-processing software has both FDA clearances and European CE marking. Our digital health segment provides these solutions to RadNet and to over 400 customers in the United States and Europe.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
We grow our imaging center business through a combination of organic growth as well as acquisitions and joint ventures. In the discussion below, the "same center" metrics are based on imaging centers that were in operation throughout the period of January 1, 2023 through December 31, 2024. Excluded amounts relate to imaging centers that were acquired or divested between January 1, 2023 through December 31, 2024.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
Consistent with the higher procedure volumes noted above, our staffing levels were adjusted to support the influx of patients seeking radiology procedures. Additionally, we are continuing to face inflation in employee wage rates as we compete for talent in a tight labor market, further impacted by the October 2024 increase in California's minimum wage for healthcare workers.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
The increase in medical supplies expense was driven by our higher patient volume and product shift towards more advanced imaging modalities. The increase in PETHC procedures related to prostate cancer and suspected Alzheimer studies also raised medical supplies expense due to the requirement for high-cost isotope tracers.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
We grow our imaging center business through a combination of organic growth as well as acquisitions and joint ventures. In the discussion below, same center metrics are based on imaging centers that were in operation throughout the period of January 1, 2022 through December 31, 2023. Excluded amounts relate to imaging centers that were acquired or divested between January 1, 2022 through December 31, 2023.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
Overall revenue change was driven by procedure volume growth of 5.7% compared to the same period in the prior year. On a same center basis, the increase in revenue was largely attributable to product mix as advanced radiology procedures of MRI, PET, and CT expanded at combined 7.2% to provide the major portion of the revenue growth.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
Similar to the prior year, growth in procedure volumes precipitated increases in salary expenses to meet additional professional staffing needs and we increased salaries to retain our skilled work force in the current tight labor market.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
The decrease in building and equipment rental was the result of our contribution of Phoenix, AZ imaging centers in connection with the formation of the Arizona Diagnostic Radiology Group joint venture in November 2022 and from the buyout of radiology equipment lease contracts during the year.
Read it in 10-K Mar 3, 2025 at sec.gov
RewordedMD&A
Common Stockholders $ (18,652) $ 2,793 $ 3,044 $ 10,650 Income taxes 14,862 6,026 8,473 9,361 Interest expense 69,913 79,849 64,483 50,841 Severance costs 3,145 1,902 3,778 946 Depreciation and amortization 152,127 137,838 128,391 115,877 Non-cash employee stock-based compensation 54,601 29,833 26,785 23,770 Loss on sale and disposal of equipment and other 9,658 2,276 2,187 2,529 Non-cash change in fair value of interest rate hedge 7,112 8,006 8,185 (39,621) Other (income) expenses (32,066) (24,916) (6,354) 1,833 Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI 20,155 14,995 1,308 — Lease abandonment charges 8,563 2,478 5,146 — Gain on contribution of imaging centers into joint venture — — (16,808) — Loss on extinguishment of debt and related expenses — 11,292 — 731 Legal settlements — — 2,197 Change in estimate related to refund liability — — 8,089 Non-cash change to contingent consideration 110 1,974 (4,075) 47 Acquisition related non-cash intangible adjustment — — 3,950 — Non-operational rent expenses 3,247 4,233 3,629 4,297 Acquisition transaction costs 7,446 880 222 927 Adjusted EBITDA - Radnet, Inc. $300,221 $279,459 $232,344 $192,474 NOTE Adjusted EBITDA - Imaging Center Segment 284,710 264,901 225,846 190,695 Adjusted EBITDA - Digital Health Segment $ 15,511 $ 14,558 $ 6,498 $ 1,779
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
Balance Sheet Data as of December 31, 2024 2023 2022 Cash and cash equivalents $ 740,020 $ 342,570 Accounts receivable 185,821 163,707 Working capital (exclusive of current operating lease liability) 596,158 197,805 Stockholders' equity 1,133,410 813,359 Income Statement data for the years ended December 31, 2025 2024 2023 Total revenue $ 2,040,210 $ 1,829,664 $ 1,616,630 $ 1,430,061 Net (loss) income attributable to RadNet RadNet, Inc. common stockholders (18,652) 2,793 3,044 10,650
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
Years Ended December 31, 2025 2024 2023 2022 REVENUE Service fee revenue 93.8% 92.5% 90.5% 89.4% Revenue under capitation arrangements 6.2% 7.5% 9.5% 10.6% Total service revenue 100.0% 100.0% 100.0% OPERATING EXPENSES Cost of operations, excluding depreciation and amortization 88.5% 86.4% 86.3% 88.4% Lease abandonment charges 0.4% 0.1% 0.3% —% Depreciation and amortization 7.5% 7.5% 7.9% 8.1% Gain on contribution of imaging centers into joint venture —% —% (1.0)% —% Loss on sale and disposal of equipment 0.5% 0.1% 0.1% 0.2% Severance costs 0.2% 0.1% 0.2% 0.1% Total operating expenses 97.0% 94.3% 93.9% 96.8% INCOME FROM OPERATIONS 3.0% 5.7% 6.1% 3.2% OTHER INCOME AND EXPENSES Interest expense 3.4% 4.4% 4.0% 3.6% Equity in earnings of joint ventures (0.7)% (0.8)% (0.4)% (0.7)% Non-cash change in fair value of interest rate swaps 0.3% 0.4% 0.5% (2.8)% Debt restructuring and extinguishment expenses —% 0.6% —% 0.1% Other income (1.6)% (1.4)% (0.4)% 0.1% Total other expenses 1.5% 3.3% 3.7% 0.3% 3.8% INCOME BEFORE INCOME TAXES 1.6% 2.5% 2.4% 3.0% Provision for income taxes (0.7)% (0.3)% (0.5)% (0.7)% NET INCOME 2.1% 0.8% 2.0% 1.8% 2.3% Net income attributable to noncontrolling interest 1.7% 2.0% 1.7% 1.6% NET (LOSS) INCOME ATTRIBUTABLE TO RADNET, INC.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
Years Ended December 31, 2025 2024 2023 Salaries and professional reading fees, excluding stock-based compensation $ 984,281 1,083,550 $ 853,327 984,280 Stock-based compensation 44,674 26,863 24,574 Building and equipment rental 127,798 121,514 117,405 Medical supplies 126,126 103,189 86,213 Other operating expenses* 275,587 271,672 355,225 303,952 Cost of operations 1,511,434 1,353,191 1,737,373 1,539,798 Depreciation and amortization 136,297 127,142 120,141 Gain on contribution of imaging centers into joint venture — (16,808) Lease abandonment charges 8,563 2,478 5,146 Loss on sale and disposal of equipment 9,821 2,257 2,191 Severance costs 1,797 1,095 1,973 Total operating expenses $ 1,644,406 1,893,851 $ 1,465,834 1,672,770
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
The increase decrease in interest expense was the result in the general increase in term loan debt primarily due to the refinancing repricing transaction of our Barclays credit facility Revolving Credit Facility (as defined in April the notes to our consolidated financial statements) in the fourth quarter of 2024, partially offset by which resulted in lower interest rates compared to the same period in the prior year.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
Balance Sheet Data as of December 31, 2025 2024 2023 2022 Cash and cash equivalents $ 767,215 $ 740,020 $ 342,570 Accounts receivable 200,317 185,821 163,707 Working capital (exclusive of current operating lease liability) 507,298 596,158 197,805 Stockholders' equity 1,355,886 1,133,410 813,359 Income Statement data for the years ended December 31, Total revenue $ 1,829,664 $ 1,616,630 $ 1,430,061 Net income attributable to RadNet common stockholders 2,793 3,044 10,650
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
The portfolio of AI and software solutions is anchored by eRad, Inc.'s RIS/PACS, informatics designed specifically for outpatient radiology Enterprise Operations solutions (traditionally knowns as RIS), Enterprise Imaging solutions (traditionally known as PACS), and Clinical AI solutions, enabled by the DeepHealth OS, a cloud-native operating system that helps operate all connects critical aspects of the radiology service line from scheduling and patient preparation to technologist workflow to interpretation and referral management.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
The As of December 31, 2025, the valuation of assets acquired and liabilities assumed has not yet been finalized as of December 31, 2024, fair value determination is preliminary and subject to change. change, primarily with respect to the valuation of deferred taxes.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
The $12.2 million increase in cash Cash provided by operating financing activities for the year ended December 31, 2024 2025 decreased by $325.7 million compared to the year ended December 31, 2023 was primarily driven by an increase in income from operations. 2024.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
Cash provided by operating activities for the year ended December 31, 2024 2025 included $289.5 $308.6 million in of net income reconciling adjustments income, adjusted for non-cash items such as depreciation and amortization, non-cash lease expense, stock-based compensation and deferred taxes, offset by a $56.5 $9.8 million change in assets and liabilities.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
Stock-based compensation increased $2.3 $17.8 million, or 9.3%, 66.3%, to approximately $44.7 million for the year ended December 31, 2025 compared to $26.9 million for the year ended December 31, 2024 compared to $24.6 million for the year ended December 31, 2023. 2024.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2025 2024 2023 2022 Segment net loss $ (30,299) $ (19,925) $ (5,154) $ (6,476) Stock Compensation 9,927 2,971 2,211 2,782 Depreciation & Amortization 15,831 10,696 8,250 6,852 Other operating loss (163) 19 (4) 23 Other income — 5,419 4,537 1,920 Severance 1,348 807 1,805 20 Income taxes (2,011) (424) (1,906) (3,342) Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI 20,155 14,995 — — Non-cash change to contingent consideration 710 — (7,191) — Acquisition related to non-cash intangible adjustment — — 3,950 — Adjusted EBITDA - Digital Health Segment $ 15,511 $ 14,558 $ 6,498 $ 1,779
Read it in 10-K Mar 2, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RDNT/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.